Abstract
The drugs currently used to treat the negative symptoms of schizophrenia are inadequate, and the methods used to evaluate their efficacy impractical and conceptually flawed. I will attempt to clarify these issues, but they are complex, and the solutions I suggest will not be completely satisfactory.